Trending Stock News

EPS for Caladrius Biosciences, Inc. (CLBS) Expected At $-0.82; Cutera Has 1.51 Sentiment

Cutera, Inc. (NASDAQ:CUTR) Logo

Cutera Inc (CUTR) investors sentiment increased to 1.51 in 2017 Q4. It’s up 0.38, from 1.13 in 2017Q3. The ratio has improved, as 92 investment professionals started new or increased equity positions, while 61 sold and decreased holdings in Cutera Inc. The investment professionals in our database now hold: 12.51 million shares, up from 11.40 million shares in 2017Q3. Also, the number of investment professionals holding Cutera Inc in top ten equity positions decreased from 2 to 1 for a decrease of 1. Sold All: 15 Reduced: 46 Increased: 44 New Position: 48.

Analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS) to report $-0.82 EPS on May, 21.They anticipate $0.30 EPS change or 26.79% from last quarter’s $-1.12 EPS. After having $-0.40 EPS previously, Caladrius Biosciences, Inc.’s analysts see 105.00% EPS growth. The stock decreased 0.24% or $0.01 during the last trading session, reaching $4.08. About 20,567 shares traded. Caladrius Biosciences, Inc. (NASDAQ:CLBS) has risen 20.65% since May 12, 2017 and is uptrending. It has outperformed by 9.10% the S&P500.

Since January 1, 0001, it had 0 buys, and 4 sales for $1.10 million activity.

Cutera, Inc., a medical device company, designs, develops, makes, markets, and services laser and other energy based aesthetics systems worldwide. The company has market cap of $510.61 million. The firm offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. It has a 18.36 P/E ratio. It also provides excel V, a vascular and benign pigmented lesion treatment platform; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, fine lines, and laxity.

More important recent Cutera, Inc. (NASDAQ:CUTR) news were published by: Seekingalpha.com which released: “Cutera’s Plunge Doesn’t Look Like A Buying Opportunity” on May 10, 2018, also Nasdaq.com published article titled: “Mid-Day Market Update: Crude Oil Up Over 3%; Extreme Networks Shares Plummet”, Benzinga.com published: “Mid-Afternoon Market Update: Dow Up Over 200 Points; Caesarstone Shares Slide” on May 09, 2018. More interesting news about Cutera, Inc. (NASDAQ:CUTR) was released by: Globenewswire.com and their article: “Research Report Identifies Rockwell Medical, Peoples, Cutera, Barrett Business Services, Cray, and Hawkins with …” with publication date: May 01, 2018.

Summit Creek Advisors Llc holds 1.58% of its portfolio in Cutera, Inc. for 185,043 shares. Teton Advisors Inc. owns 318,000 shares or 1.33% of their US portfolio. Moreover, De Burlo Group Inc has 0.76% invested in the company for 82,600 shares. The California-based Eam Investors Llc has invested 0.73% in the stock. Bogle Investment Management L P De, a Massachusetts-based fund reported 185,174 shares.

Ratings analysis reveals 100% of Cutera’s analysts are positive. Out of 2 Wall Street analysts rating Cutera, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $22.0 while the high is $27.0. The stock’s average target of $24.50 is -34.58% below today’s ($37.45) share price. CUTR was included in 2 notes of analysts from January 4, 2017. As per Tuesday, April 11, the company rating was initiated by Sidoti. Maxim Group maintained Cutera, Inc. (NASDAQ:CUTR) on Wednesday, January 4 with “Buy” rating.

The stock increased 5.64% or $2 during the last trading session, reaching $37.45. About 632,567 shares traded or 203.12% up from the average. Cutera, Inc. (CUTR) has risen 147.90% since May 12, 2017 and is uptrending. It has outperformed by 136.35% the S&P500.

More recent Caladrius Biosciences, Inc. (NASDAQ:CLBS) news were published by: Globenewswire.com which released: “Caladrius Biosciences Reports 2018 First Quarter Financial Results” on May 10, 2018. Also Nasdaq.com published the news titled: “Caladrius Biosciences to Participate at the 15th International Symposium on Cardiovascular Regeneration and Repair” on May 07, 2018. Nasdaq.com‘s news article titled: “Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 …” with publication date: May 03, 2018 was also an interesting one.

Cutera, Inc. (NASDAQ:CUTR) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *